DVHGF 0.17 Devonian Health Group Inc.
| Range: | 0.01-0.2138 | Vol Avg: | 230 | Last Div: | 0 | Changes: | -0.05 |
| Beta: | 1.28 | Cap: | 0.02B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Mon Sep 19 2022 | Empoloyees: | 6 | ||
| CUSIP: | CIK: | ISIN: | CA2518341078 | Country: | CA | ||
| CEO: | Mr. Luc D. Gregoire CA, CPA | Website: | https://groupedevonian.com | ||||
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow